Genocury launched the in vivo CD19 CAR-T therapy to reach the clinical stage, demonstrating exceptional safety, efficiency and durability.<\/i><\/p>\n
Results are attained without requiring lymphodepletion.<\/i><\/p>\n
SHENZHEN, China<\/span><\/span>, April 30, 2025<\/span><\/span> \/PRNewswire\/ — Genocury Biotech<\/span> today revealed groundbreaking clinical data from its noval in vivo CD19 CAR-T therapy in relapsed\/refractory diffuse large B-cell lymphoma (R\/R DLBCL)<\/b>, a notoriously aggressive blood cancer. In a investigator-initiated trial (IIT) led by the Hematology Department at Tongji Hospital, a heavily pretreated relapsed\/refractory (R\/R) patient with advanced DLBCL achieved complete remission (CR)<\/b>\u00a0after\u00a01 month of\u00a0the in vivo CAR-T treatment, with durable response sustained over three months. Notably, the treatment eliminated the need for lymphodepletion<\/b>, a standard yet toxic preconditioning step in traditional CAR-T protocols.<\/p>\n Clinical Breakthrough: <\/b>Redefining <\/b>Safety, Efficacy, and Speed<\/b><\/p>\n Key\u00a0trial findings:<\/p>\n 1. Rapid and Deep Response<\/b>:<\/p>\n A\u00a0relapsed DLBCL <\/b>male patient\u00a0achieved complete hematological remission (CR) within 28 days following a single dose of Genocury’s CD19 in vivo\u00a0CAR-T<\/b>\u00a0without lymphodepletion<\/b>.\u00a0Flow cytometric analysis revealed significant\u00a0CAR-T cell\u00a0expansion kenetics, with sustained therapeutic efficacy confirmed through 90-day follow-up monitoring.<\/p>\n 2.\u00a0Unprecedented Safety Profile<\/b>:<\/b><\/p>\n Unlike conventional CAR-T, which carries a ~50% risk of cytokine release syndrome (CRS)\u00a0and neurotoxicity, this novel therapeutic approach demonstrated complete absence of:\u00a0<\/p>\n Reimagining CAR-T: In Vivo Engineering Breakthroughs<\/b><\/p>\n Genocury’s in vivo CAR-T platform<\/b> overcomes two critical roadblocks\u00a0in current CAR-T therapy:<\/p>\n Statement from Prof. Jia<\/b>\u00a0Wei , M.D., Ph.D.<\/b><\/p>\n PI (principal investigator),\u00a0Tongji Hospital Cancer Center (Wuhan<\/span>)<\/b> About <\/b>Genocury<\/b>\u00a0Biotech<\/b> About Tongji Hospital Hematology Department\n
\n
\u00a0“<\/i>In this groundbreaking case, we observed t<\/i>he patient treated with <\/i>Genocury’s CD19 in vivo CAR-T <\/i>achieved complete remission <\/i>through 90-day follow-up – achieved <\/i>without<\/b><\/i>\u00a0any<\/b><\/i>\u00a0lymphodepletion<\/b><\/i>, <\/i>which fundamentally challenges current cellular therapy dogma” said Dr. Jia Wei<\/span>, <\/i>“This therapy combines the benefits of autologous CAR-T with the accessibility of universal therapies, potentially ending the era of unaffordable cancer treatments. <\/i>T<\/i>his could democratize access to CAR-T globally, we are<\/i>\u00a0very<\/i>\u00a0excited to advance this paradigm-shifting approach.”<\/i><\/p>\n
Shenzhen Genocury Biotech<\/span> Co., Ltd. is a clinical-stage biotechnology pioneer redefining in vivo cell engineering through its proprietary Vivoexpress\u2122 platform. This modular delivery system enables targeted delivery of genetic payloads with organ-specific tropism. The company dedicated to deliver next-generation immunotherapies for oncology and autoimmune disorders by developing universal cell and gene therapies for patients worldwide.<\/p>\n
<\/b>Since its establishment in 1959, the Hematology Department of Tongji Hospital is one of China’s<\/span> earliest and most prestigious hematology centers. Recognized for clinical excellence and innovative research, it evolved into a premier academic medical center well known as a national key discipline (2007) and national clinical key specialty (2011), and serves as the largest cell immunotherapy center in Hubei Province<\/span>.<\/span> With 74 medical professionals, including 22 full professors and 50 PhD practitioners, the department collectively manage over 10.000 annual patient cases. Specializing in complex hematologic malignancies ranging from leukemia, lymphoma, and myeloma to multiple other hematologic malignancies, Tongji Hospital Hematology Department solidifies its position as a leading clinical and research institution in Asia<\/span>.<\/p>\n